Cochrane · systematic review · CD011314
External beam radiotherapy for unresectable hepatocellular carcinoma
Abdel‐Rahman, O, Elsayed, Z · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
11
current version
GRADE rated
6
No studies
5
Included studies
NR
No studies 5 · 45.5%Ungraded 0 · 0%Very low 4 · 36.4%Low 2 · 18.2%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
External beam radiotherapy (EBRT) plus transarterial chemoembolisation (TACE) versus TACE alone for unresectable hepatocellular carcinoma
Population: people with unresectable hepatocellular carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality (at maximum 1‐year External beam radiotherapy (EBRT) plus transarterial chemoembolisation (TACE) vs TACE alone | RR 0.51 [0.41, 0.62] | 9 studies · 786 participants | Low Downgraded: risk of bias, publication bias |
Health‐related quality of life External beam radiotherapy (EBRT) plus transarterial chemoembolisation (TACE) vs TACE alone | no estimate extracted | NR | No studies |
Serious adverse events External beam radiotherapy (EBRT) plus transarterial chemoembolisation (TACE) vs TACE alone | no estimate extracted | NR | No studies |
Complete response plus partial response Length of External beam radiotherapy (EBRT) plus transarterial chemoembolisation (TACE) vs TACE alone | RR 1.58 [1.4, 1.78] | 7 studies · 620 participants | Low Downgraded: risk of bias, publication bias |
Elevated alanine aminotransferase Length of External beam radiotherapy (EBRT) plus transarterial chemoembolisation (TACE) vs TACE alone | RR 1.41 [1.08, 1.84] | 3 studies · 232 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Elevated total bilirubin Length of External beam radiotherapy (EBRT) plus transarterial chemoembolisation (TACE) vs TACE alone | RR 2.69 [1.34, 5.4] | 2 studies · 172 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
External beam radiotherapy (EBRT) versus transarterial chemoembolisation (TACE) for unresectable hepatocellular carcinoma
Population: people with unresectable hepatocellular carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality (at 1 year) External beam radiotherapy (EBRT) vs transarterial chemoembolisation (TACE) | RR 1.21 [0.97, 1.5] | 3 studies · 152 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Serious adverse events External beam radiotherapy (EBRT) vs transarterial chemoembolisation (TACE) | no estimate extracted | NR | No studies |
Complete response plus partial response Length of External beam radiotherapy (EBRT) vs transarterial chemoembolisation (TACE) | no estimate extracted | 1 study · 41 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Elevated alanine aminotransferase External beam radiotherapy (EBRT) vs transarterial chemoembolisation (TACE) | no estimate extracted | NR | No studies |
Elevated total bilirubin External beam radiotherapy (EBRT) vs transarterial chemoembolisation (TACE) | no estimate extracted | NR | No studies |